Bard Bullish On 2005 Surgical Urology Sales; Tegress To Launch Mid-Year
This article was originally published in The Gray Sheet
Executive Summary
Bard says a 43% rise in sales of surgical stress urinary incontinence offerings such as the Contigen collagen-based injectable implant helped Q4 urology revenue grow 14% to $130.4 mil